Opioid Use Disorder: Zolunicant's Potential for Unmet Treatment Needs...
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development...
MindMed Reports First Quarter 2022 Financial Results and Business...
MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and...
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial...
You are leaving MindMed and will be automatically redirected to ${url} in a moment.
Change your mind?
Return to Mindmed